Maravai LifeSciences Holdings, Inc.

Nasdaq : MRVI

Provides genetic products and testing services for drug development and research.

  • Filed 29-10-2020
  • Set Terms --
  • IPO Date 20-11-2020
  • Lock Up 19-02-2021
Текущая цена
43.2 $
Текущая доходность
60 %
Доходность за 1 день торгов
10.56 %
Доходность по итогам
Lock up периода
32.26 %
Рейтинг от IPO.one:
Дата IPO
20-11-2020
Объем размещения
60 000 000
Размер сделки ($M)
1620
Диапазон цены
24-27 $
Цена IPO
27 $
Lock Up
19-02-2021
Год основания
2014
Головной офис
San Diego, CA
Веб сайт
Юристы
Davis Polk Kirkland & Ellis
Аудитор
EY
Андеррайтер
Morgan Stanley

Описание компании

We are a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Our more than 5,000 customers as of September 30, 2020 include the top 20 global biopharmaceutical companies ranked by research and development expenditures according to industry consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutes and in vitro diagnostics companies. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Our businesses principally serve high growth market segments in biopharmaceutical development and manufacturing. We estimate that the market segments we serve are growing at a weighted average blended rate of 20% per annum. In particular, the field of cell and gene therapy has emerged as one of the fastest growing treatment modalities to address a host of human conditions.